CORRECTING and REPLACING Bronstein, Gewirtz & Grossman, LLC Investigates Integra LifeSciences Holdings Corp.
January 09 2012 - 10:30AM
Business Wire
Headline should read Bronstein, Gewirtz &
Grossman, LLC Investigates Integra LifeSciences Holdings Corp.
(sted Bronstein, Gewirtz & Grossman, LLC Investigates
LifeSciences Holdings Corp.)
The corrected release reads:
BRONSTEIN, GEWIRTZ & GROSSMAN, LLC
INVESTIGATES INTEGRA LIFESCIENCES HOLDINGS CORP.
Attorney Advertising--Bronstein, Gewirtz &
Grossman, LLC is investigating potential claims on behalf of
purchasers of the securities of Integra LifeSciences Holdings,
Corp. (“Integra” or the “Company”) (NASDAQ:IART), concerning
whether the company and certain of its officers and directors have
violated federal securities laws.
On Friday, January 6, 2012, shares of Integra,
a maker of orthopedic implants, fell $6.01 or almost 20% to close
at $24.49 after cutting its revenue forecast and saying U.S.
regulators cited the company for mold at a factory. In addition,
Integra recently received a warning letter from the US Food and
Drug Administration (“FDA”) pertaining to quality systems and
compliance issues at its collagen manufacturing facility in
Plainsboro, New Jersey. Earlier in August, the company received a
Form 483 observation from the FDA regarding manufacturing concerns
at this collagen manufacturing facility. Collagen products
currently represent roughly 23% of total sales and are manufactured
at two facilities (the second in Puerto Rico).
If you are aware of any facts relating to this
investigation, or purchased shares of Integra, you can assist this
investigation by contacting either Peretz Bronstein or Eitan
Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484
or via email eitan@bgandg.com. Those who inquire by e-mail are
encouraged to include their mailing address and telephone
number.
Bronstein, Gewirtz & Grossman, LLC is a
corporate litigation boutique. Our primary expertise is the
aggressive pursuit of litigation claims on behalf of our clients.
In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm’s
expertise includes general corporate work, private securities
offerings, and securities arbitration.
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From May 2024 to Jun 2024
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Jun 2023 to Jun 2024